LFG
BMY.RT

LifePlan Financial Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

LifePlan Financial Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$0 Hold
48
– – ﹤0.01% 608
2020
Q2 		$0 Hold
48
– – ﹤0.01% 596
2020
Q1 		$0 Hold
48
– – ﹤0.01% 587
2019
Q4 		$0 Buy
+48
New +$125 ﹤0.01% 585

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LifePlan Financial Group's BMY.RT Position: Q3 2020 in Review

LifePlan Financial Group held its Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) position steady in Q3 2020 at 48 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #608.

LifePlan Financial Group first reported a position in BMY.RT in Q4 2019 and has held it in 4 quarters since. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • LifePlan Financial Group held 48 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $0 as of Q3 2020.
  • LifePlan Financial Group left its Bristol-Myers Squibb Company Contingent Value Rights share count unchanged in Q3 2020.
  • Bristol-Myers Squibb Company Contingent Value Rights made up ﹤0.01% of LifePlan Financial Group's portfolio in Q3 2020, its #608 holding.
  • LifePlan Financial Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and has held it in 4 quarters since.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on LifePlan Financial Group's 13F filing for Q3 2020, filed 30 Oct 2020.